No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Sprycel is a drug used to treat certain types of leukemia, a type of cancer of the blood and bone marrow. It is a tyrosine kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Sprycel is used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also used to treat adults with newly diagnosed Ph+ ALL.
Sprycel is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2006. It is one of several drugs used to treat leukemia, including Gleevec, Tasigna, and Bosulif. Sprycel is generally well-tolerated, with the most common side effects being nausea, vomiting, diarrhea, and headache.
In the Sprycel market, some of the major players include Bristol-Myers Squibb, Novartis, Pfizer, and GlaxoSmithKline. These companies manufacture and distribute the drug, as well as provide support services to patients. Other companies involved in the market include Cephalon, Merck, and Teva Pharmaceuticals. Show Less Read more
